| 269.12 -2.19 (-0.81%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 321.14 | 1-year : | 375.09 |
| Resists | First : | 274.95 | Second : | 321.14 |
| Pivot price | 267.68  |
|||
| Supports | First : | 266.03 | Second : | 260.51 |
| MAs | MA(5) : | 270.63 |
MA(20) : | 268.06 |
| MA(100) : | 262.54 |
MA(250) : | 249.21 |
|
| MACD | MACD : | 0.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.9 |
D(3) : | 71.3 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 288.45 | Low : | 211.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AMGN ] has closed below upper band by 38.5%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 272.32 - 273.64 | 273.64 - 274.94 |
| Low: | 264.87 - 266.55 | 266.55 - 268.21 |
| Close: | 266.02 - 268.67 | 268.67 - 271.29 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Fri, 08 Dec 2023
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Thu, 07 Dec 2023
Amgen Inc. stock rises Thursday, still underperforms market - MarketWatch
Thu, 07 Dec 2023
Can Amgen, Inc. (AMGN) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Thu, 07 Dec 2023
Amgen (NASDAQ:AMGN) shareholders have earned a 9.8% CAGR over the last five years - Yahoo Finance
Wed, 06 Dec 2023
Amgen: Relative Valuation Remains Unattractive - Yahoo Finance
Wed, 06 Dec 2023
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 535 (M) |
| Shares Float | 534 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 79.3 (%) |
| Shares Short | 6,770 (K) |
| Shares Short P.Month | 6,360 (K) |
| EPS | 14.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.31 |
| Profit Margin | 28.2 % |
| Operating Margin | 38.9 % |
| Return on Assets (ttm) | 7.8 % |
| Return on Equity (ttm) | 133.8 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 37.22 |
| Sales Per Share | 50.13 |
| EBITDA (p.s.) | 24.85 |
| Qtrly Earnings Growth | -19.2 % |
| Operating Cash Flow | 10,580 (M) |
| Levered Free Cash Flow | 8,900 (M) |
| PE Ratio | 19.14 |
| PEG Ratio | 2.7 |
| Price to Book value | 18.8 |
| Price to Sales | 5.36 |
| Price to Cash Flow | 13.61 |
| Dividend | 2.13 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|